Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
UBS
Merck
US Department of Justice
Baxter
Moodys

Generated: July 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,254,286

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,254,286 protect, and when does it expire?

Patent 9,254,286 protects ZERVIATE and is included in one NDA.

Protection for ZERVIATE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifteen patent family members in five countries.

Summary for Patent: 9,254,286
Title:Ophthalmic formulations of cetirizine and methods of use
Abstract: The present invention provides stable topical formulations of cetirizine that provide a comfortable formulation when instilled in the eye and is effective in the treatment of allergic conjunctivitis and/or allergic conjunctivitis. The invention further provides methods of treating allergic conjunctivitis and/or allergic rhinoconjunctivitis in a subject in need of such treatment by topical application of the cetirizine formulations of the invention directly to the eye.
Inventor(s): Abelson; Mark B. (Andover, MA), Chapin; Matthew J. (Amesbury, MA), Gomes; Paul (Haverhill, MA), Minno; George (Suwanee, GA), Nice; Jackie (Medford, MA)
Assignee: Aciex Therapeutics, Inc. (Boston, MA)
Application Number:12/724,128
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,254,286
Patent Claim Types:
see list of patent claims
Formulation; Compound; Delivery; Device;

Drugs Protected by US Patent 9,254,286

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eyevance ZERVIATE cetirizine hydrochloride SOLUTION/DROPS;OPHTHALMIC 208694-001 May 30, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Argus Health
Julphar
US Department of Justice
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.